Puldysa is thought to have a dual effect in Duchenne – mitochondrial activation and protection. Puldysa is thought to increase the energy output of the cells’ mitochondria – the parts (“factories”) of the cell that generate all of a cells’ energy. Mitochondria produce the energy necessary for the cell functioning through a process called “cellular respiration” which requires oxygen and produces energy. During cellular respiration, some toxic forms of oxygen (called oxygen free radicals) can be produced. These free radicals must be neutralized by other substances to avoid cellular damage. Puldysa is expected to act as a neutralizer of these toxic forms of oxygen. Thus, Puldysa is expected to have an antioxidant effect, and consequently prevent cellular damage.
A Phase 3 study is currently actively recruiting.
On April 1, 2020, Santhera Pharmaceuticals shared an update with the community regarding the SIDEROS clinical trial and their activities during the COVID-19 epidemic.
This program is sponsored by Santhera Pharmaceuticals.
|A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids|
OPEN LABEL EXTENSION
|Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)|
Santhera Presents at the PPMD 2019 Annual Conference
Webinar: Santhera Update to the Duchenne CommunityParent Project Muscular Dystrophy and Santhera Pharmaceuticals hosted a webinar May 8, 2019 to provide the community with an update about respiratory health in Duchenne muscular dystrophy and the ongoing SIDEROS clinical trial.
Santhera Presents at the PPMD 2018 Annual Conference
Webinar: Idebenone Clinical Trials in DuchenneParent Project Muscular Dystrophy and Santhera Pharmaceuticals hosted a webinar on March 9, 2017 to discuss idebenone clinical trials in Duchenne.